Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale

Michael Hawkes, Robert Opika Opoka, Sophie Namasopo, Christopher Miller, Andrea L. Conroy, Lena Serghides, Hani Kim, Nisha Thampi, W. Conrad Liles, Chandy John, Kevin C. Kain

Research output: Contribution to journalArticle

17 Citations (Scopus)

Abstract

We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy. The rationale for the hypothesized efficacy of iNO rests on: (1) biological plausibility, based on known actions of NO in modulating endothelial activation; (2) pre-clinical efficacy data from animal models of experimental cerebral malaria; and (3) a human trial of the NO precursor l-arginine, which improved endothelial function in adults with severe malaria. iNO is an attractive new candidate for the adjunctive treatment of severe malaria, given its proven therapeutic efficacy in animal studies, track record of safety in clinical practice and numerous clinical trials, inexpensive manufacturing costs, and ease of administration in settings with limited healthcare infrastructure. We plan to test this hypothesis in a randomized controlled trial (ClinicalTrials.gov Identifier: NCT01255215).

Original languageEnglish (US)
Pages (from-to)437-444
Number of pages8
JournalMedical Hypotheses
Volume77
Issue number3
DOIs
StatePublished - Sep 2011
Externally publishedYes

Fingerprint

Malaria
Nitric Oxide
Cerebral Malaria
Antimalarials
Arginine
Therapeutics
Randomized Controlled Trials
Animal Models
Clinical Trials
Delivery of Health Care
Safety
Costs and Cost Analysis

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Hawkes, M., Opoka, R. O., Namasopo, S., Miller, C., Conroy, A. L., Serghides, L., ... Kain, K. C. (2011). Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale. Medical Hypotheses, 77(3), 437-444. https://doi.org/10.1016/j.mehy.2011.06.003

Nitric oxide for the adjunctive treatment of severe malaria : Hypothesis and rationale. / Hawkes, Michael; Opoka, Robert Opika; Namasopo, Sophie; Miller, Christopher; Conroy, Andrea L.; Serghides, Lena; Kim, Hani; Thampi, Nisha; Liles, W. Conrad; John, Chandy; Kain, Kevin C.

In: Medical Hypotheses, Vol. 77, No. 3, 09.2011, p. 437-444.

Research output: Contribution to journalArticle

Hawkes, M, Opoka, RO, Namasopo, S, Miller, C, Conroy, AL, Serghides, L, Kim, H, Thampi, N, Liles, WC, John, C & Kain, KC 2011, 'Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale', Medical Hypotheses, vol. 77, no. 3, pp. 437-444. https://doi.org/10.1016/j.mehy.2011.06.003
Hawkes M, Opoka RO, Namasopo S, Miller C, Conroy AL, Serghides L et al. Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale. Medical Hypotheses. 2011 Sep;77(3):437-444. https://doi.org/10.1016/j.mehy.2011.06.003
Hawkes, Michael ; Opoka, Robert Opika ; Namasopo, Sophie ; Miller, Christopher ; Conroy, Andrea L. ; Serghides, Lena ; Kim, Hani ; Thampi, Nisha ; Liles, W. Conrad ; John, Chandy ; Kain, Kevin C. / Nitric oxide for the adjunctive treatment of severe malaria : Hypothesis and rationale. In: Medical Hypotheses. 2011 ; Vol. 77, No. 3. pp. 437-444.
@article{6e64902f109341b38e0319befa3d86d3,
title = "Nitric oxide for the adjunctive treatment of severe malaria: Hypothesis and rationale",
abstract = "We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy. The rationale for the hypothesized efficacy of iNO rests on: (1) biological plausibility, based on known actions of NO in modulating endothelial activation; (2) pre-clinical efficacy data from animal models of experimental cerebral malaria; and (3) a human trial of the NO precursor l-arginine, which improved endothelial function in adults with severe malaria. iNO is an attractive new candidate for the adjunctive treatment of severe malaria, given its proven therapeutic efficacy in animal studies, track record of safety in clinical practice and numerous clinical trials, inexpensive manufacturing costs, and ease of administration in settings with limited healthcare infrastructure. We plan to test this hypothesis in a randomized controlled trial (ClinicalTrials.gov Identifier: NCT01255215).",
author = "Michael Hawkes and Opoka, {Robert Opika} and Sophie Namasopo and Christopher Miller and Conroy, {Andrea L.} and Lena Serghides and Hani Kim and Nisha Thampi and Liles, {W. Conrad} and Chandy John and Kain, {Kevin C.}",
year = "2011",
month = "9",
doi = "10.1016/j.mehy.2011.06.003",
language = "English (US)",
volume = "77",
pages = "437--444",
journal = "Medical Hypotheses",
issn = "0306-9877",
publisher = "Churchill Livingstone",
number = "3",

}

TY - JOUR

T1 - Nitric oxide for the adjunctive treatment of severe malaria

T2 - Hypothesis and rationale

AU - Hawkes, Michael

AU - Opoka, Robert Opika

AU - Namasopo, Sophie

AU - Miller, Christopher

AU - Conroy, Andrea L.

AU - Serghides, Lena

AU - Kim, Hani

AU - Thampi, Nisha

AU - Liles, W. Conrad

AU - John, Chandy

AU - Kain, Kevin C.

PY - 2011/9

Y1 - 2011/9

N2 - We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy. The rationale for the hypothesized efficacy of iNO rests on: (1) biological plausibility, based on known actions of NO in modulating endothelial activation; (2) pre-clinical efficacy data from animal models of experimental cerebral malaria; and (3) a human trial of the NO precursor l-arginine, which improved endothelial function in adults with severe malaria. iNO is an attractive new candidate for the adjunctive treatment of severe malaria, given its proven therapeutic efficacy in animal studies, track record of safety in clinical practice and numerous clinical trials, inexpensive manufacturing costs, and ease of administration in settings with limited healthcare infrastructure. We plan to test this hypothesis in a randomized controlled trial (ClinicalTrials.gov Identifier: NCT01255215).

AB - We hypothesize that supplemental inhaled nitric oxide (iNO) will improve outcomes in children with severe malaria receiving standard antimalarial therapy. The rationale for the hypothesized efficacy of iNO rests on: (1) biological plausibility, based on known actions of NO in modulating endothelial activation; (2) pre-clinical efficacy data from animal models of experimental cerebral malaria; and (3) a human trial of the NO precursor l-arginine, which improved endothelial function in adults with severe malaria. iNO is an attractive new candidate for the adjunctive treatment of severe malaria, given its proven therapeutic efficacy in animal studies, track record of safety in clinical practice and numerous clinical trials, inexpensive manufacturing costs, and ease of administration in settings with limited healthcare infrastructure. We plan to test this hypothesis in a randomized controlled trial (ClinicalTrials.gov Identifier: NCT01255215).

UR - http://www.scopus.com/inward/record.url?scp=80051819586&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80051819586&partnerID=8YFLogxK

U2 - 10.1016/j.mehy.2011.06.003

DO - 10.1016/j.mehy.2011.06.003

M3 - Article

C2 - 21745716

AN - SCOPUS:80051819586

VL - 77

SP - 437

EP - 444

JO - Medical Hypotheses

JF - Medical Hypotheses

SN - 0306-9877

IS - 3

ER -